The upcoming report from Boston Scientific (BSX - Free Report) is expected to reveal quarterly earnings of $0.83 per share, indicating an increase of 10.7% compared to the year-ago period. Analysts forecast revenues of $5.39 billion, representing an increase of 6.5% year over year.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Boston Scientific metrics that are commonly tracked and projected by analysts on Wall Street.
According to the collective judgment of analysts, 'Net Sales- MedSurg- Worldwide' should come in at $1.80 billion. The estimate indicates a change of +4.8% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net Sales- Cardiovascular- Worldwide' will likely reach $3.61 billion. The estimate indicates a year-over-year change of +7.9%.
It is projected by analysts that the 'Net Sales- MedSurg- Neuromodulation- Worldwide' will reach $335.33 million. The estimate indicates a change of +10.7% from the prior-year quarter.
The average prediction of analysts places 'Net Sales- MedSurg- Endoscopy- Worldwide' at $774.10 million. The estimate indicates a year-over-year change of +5%.
Based on the collective assessment of analysts, 'Net Sales- MedSurg- Urology- Worldwide' should arrive at $694.74 million. The estimate points to a change of +2.8% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide' reaching $601.79 million. The estimate suggests a change of +2% year over year.
The consensus estimate for 'Net Sales- Cardiovascular- Interventional Cardiology & Vascular Therapies- Worldwide' stands at $1.26 billion. The estimate suggests a change of +73% year over year.
Analysts predict that the 'Net Sales- Cardiovascular- Watchman- Worldwide' will reach $553.70 million. The estimate suggests a change of +13.9% year over year.
The collective assessment of analysts points to an estimated 'Net Sales- Cardiovascular- Electrophysiology- Worldwide' of $923.15 million. The estimate indicates a change of +9.9% from the prior-year quarter.
The consensus among analysts is that 'Geographic Revenue- U.S.' will reach $3.39 billion. The estimate suggests a change of +5.1% year over year.
Analysts expect 'Geographic Revenue- Rest of the World' to come in at $1.98 billion. The estimate suggests a change of +8% year over year.
View all Key Company Metrics for Boston Scientific here>>>
Shares of Boston Scientific have experienced a change of -1.4% in the past month compared to the +0.6% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), BSX is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Bank of Nova Scotia raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 15.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,303,011 shares of the medical equipment provider’s stock after acquiring an additional 308,930 shares during the quarter. Bank of Nova Scotia owned approximately 0.15% of Boston Scientific worth $144,515,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. raised its stake in Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after acquiring an additional 1,436,550 shares in the last quarter. State Street Corp grew its holdings in shares of Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after purchasing an additional 920,495 shares during the last quarter. Capital World Investors grew its holdings in shares of Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after purchasing an additional 502,627 shares during the last quarter. Norges Bank acquired a new stake in shares of Boston Scientific during the fourth quarter worth about $2,199,395,000. Finally, Morgan Stanley increased its position in shares of Boston Scientific by 10.8% during the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after purchasing an additional 2,246,308 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.
Boston Scientific Stock Performance Shares of BSX opened at $43.67 on Friday. The stock has a market capitalization of $64.90 billion, a P/E ratio of 18.27, a P/E/G ratio of 0.82 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The company’s fifty day moving average is $47.37 and its two-hundred day moving average is $64.20.
Boston Scientific (NYSE:BSX – Get Free Report) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter last year, the business earned $0.75 EPS. The business’s revenue was up 11.6% on a year-over-year basis. On average, sell-side analysts predict that Boston Scientific Corporation will post 3.35 earnings per share for the current year.
Boston Scientific declared that its Board of Directors has initiated a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.
Wall Street Analysts Forecast Growth Several research analysts have commented on BSX shares. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Jefferies Financial Group reduced their price target on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, June 24th. Oppenheimer set a $90.00 price target on shares of Boston Scientific in a research note on Thursday, April 23rd. Truist Financial lowered their price objective on shares of Boston Scientific from $64.00 to $62.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Finally, Weiss Ratings cut shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $79.84.
Check Out Our Latest Stock Report on Boston Scientific
Insider Activity at Boston Scientific In other Boston Scientific news, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $56.49 per share, with a total value of $99,987.30. Following the acquisition, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward J. Ludwig bought 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the purchase, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 9,800 shares of company stock worth $554,012 over the last 90 days. Company insiders own 0.34% of the company’s stock.
Boston Scientific Company Profile (Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Read More Five stocks we like better than Boston Scientific Premium Retail’s Stress Test Is Separating Winners From Losers D-Wave Quantum or a Quantum ETF: Which Is the Better Bet? GE Vernova Just Sent a Mixed AI Signal to Investors Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
Andra AP fonden lifted its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 144.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 169,928 shares of the medical equipment provider’s stock after purchasing an additional 100,406 shares during the period. Andra AP fonden’s holdings in Boston Scientific were worth $10,663,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors also recently bought and sold shares of BSX. Renaissance Group LLC purchased a new position in shares of Boston Scientific during the 4th quarter worth $28,064,000. Rathbones Group PLC grew its holdings in shares of Boston Scientific by 20.9% in the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after purchasing an additional 477,680 shares during the period. Waycross Partners LLC acquired a new stake in Boston Scientific during the fourth quarter worth about $2,384,000. Meiji Yasuda America Inc acquired a new stake in Boston Scientific during the fourth quarter worth about $4,708,000. Finally, Allspring Global Investments Holdings LLC raised its stake in Boston Scientific by 6.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,173,399 shares of the medical equipment provider’s stock worth $205,843,000 after purchasing an additional 139,004 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.
Insider Buying and Selling at Boston Scientific In related news, Director Edward J. Ludwig acquired 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the purchase, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Habiger bought 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 9,800 shares of company stock valued at $554,012 in the last 90 days. Company insiders own 0.34% of the company’s stock.
Boston Scientific Trading Down 1.4% BSX opened at $43.14 on Wednesday. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The business has a fifty day simple moving average of $47.77 and a 200-day simple moving average of $64.93. The firm has a market cap of $64.12 billion, a P/E ratio of 18.05, a P/E/G ratio of 0.84 and a beta of 0.58.
Boston Scientific (NYSE:BSX – Get Free Report) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period last year, the business posted $0.75 EPS. Boston Scientific’s revenue for the quarter was up 11.6% on a year-over-year basis. On average, equities analysts expect that Boston Scientific Corporation will post 3.35 earnings per share for the current year.
Boston Scientific declared that its Board of Directors has initiated a share repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.
Wall Street Analysts Forecast Growth Several equities analysts have weighed in on BSX shares. BTIG Research reiterated a “buy” rating and issued a $65.00 target price on shares of Boston Scientific in a report on Tuesday, June 16th. Canaccord Genuity Group reduced their price target on shares of Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Daiwa Securities Group cut Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Evercore set a $65.00 target price on Boston Scientific in a research note on Monday, July 6th. Finally, Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $79.84.
Get Our Latest Research Report on BSX
About Boston Scientific (Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Articles Five stocks we like better than Boston Scientific Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAndra AP fonden Buys 35,335 Shares of Dell Technologies Inc. $DELL
NEXT HEADLINE »Arvest Bank Trust Division Purchases Shares of 62,936 Uber Technologies, Inc. $UBER
Baader Bank Aktiengesellschaft decreased its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 50.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,770 shares of the medical equipment provider’s stock after selling 12,014 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Boston Scientific were worth $728,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares during the period. State Street Corp raised its position in Boston Scientific by 1.4% in the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares in the last quarter. Capital World Investors raised its position in Boston Scientific by 1.9% in the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares in the last quarter. Norges Bank purchased a new position in shares of Boston Scientific in the 4th quarter valued at about $2,199,395,000. Finally, Morgan Stanley grew its position in shares of Boston Scientific by 10.8% during the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after buying an additional 2,246,308 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.
Boston Scientific Stock Down 1.4% BSX stock opened at $43.14 on Wednesday. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The company’s 50 day moving average is $47.77 and its two-hundred day moving average is $64.93. The stock has a market cap of $64.12 billion, a P/E ratio of 18.05, a PEG ratio of 0.84 and a beta of 0.58.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.75 EPS. Research analysts expect that Boston Scientific Corporation will post 3.35 earnings per share for the current fiscal year.
Boston Scientific declared that its board has approved a stock repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.
Insider Activity at Boston Scientific In related news, Director Edward J. Ludwig purchased 3,580 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cheryl Pegus acquired 1,770 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 9,800 shares of company stock valued at $554,012 over the last ninety days. Insiders own 0.34% of the company’s stock.
Analyst Ratings Changes Several analysts recently weighed in on BSX shares. Robert W. Baird set a $70.00 target price on shares of Boston Scientific in a report on Thursday, May 28th. Raymond James Financial reiterated an “outperform” rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Jefferies Financial Group dropped their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, June 24th. Bank of America reduced their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, The Goldman Sachs Group set a $71.00 price objective on shares of Boston Scientific in a research report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $79.84.
Read Our Latest Research Report on Boston Scientific
About Boston Scientific (Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Articles Five stocks we like better than Boston Scientific Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBeacon Financial Group Trims Stock Position in Amazon.com, Inc. $AMZN
NEXT HEADLINE »Aware Super Pty Ltd as trustee of Aware Super Makes New $160.61 Million Investment in Meta Platforms, Inc. $META
Bessemer Group Inc. reduced its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 98.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,473 shares of the medical equipment provider’s stock after selling 3,851,493 shares during the quarter. Bessemer Group Inc.’s holdings in Boston Scientific were worth $2,853,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently bought and sold shares of the business. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the second quarter worth $26,000. Swiss RE Ltd. bought a new position in shares of Boston Scientific in the fourth quarter worth $26,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific in the fourth quarter valued at $26,000. Bangor Savings Bank grew its position in shares of Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares in the last quarter. Finally, Sfam LLC bought a new stake in shares of Boston Scientific during the 4th quarter valued at $29,000. 89.07% of the stock is owned by institutional investors.
Boston Scientific Trading Down 1.4% Boston Scientific stock opened at $43.14 on Wednesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The stock has a market cap of $64.12 billion, a P/E ratio of 18.05, a PEG ratio of 0.84 and a beta of 0.58. The firm’s fifty day moving average price is $47.77 and its 200-day moving average price is $64.93.
Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter last year, the company earned $0.75 earnings per share. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. Equities research analysts forecast that Boston Scientific Corporation will post 3.35 earnings per share for the current fiscal year.
Boston Scientific declared that its board has approved a share buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.
Insiders Place Their Bets In other Boston Scientific news, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director David C. Habiger acquired 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the transaction, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. The trade was a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 9,800 shares of company stock worth $554,012 in the last ninety days. 0.34% of the stock is currently owned by insiders.
Analysts Set New Price Targets BSX has been the topic of a number of recent research reports. Jefferies Financial Group dropped their price objective on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, June 24th. Mizuho reduced their target price on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Wells Fargo & Company reiterated an “equal weight” rating and set a $55.00 price target (down from $75.00) on shares of Boston Scientific in a research report on Thursday, May 28th. Canaccord Genuity Group lowered their price target on shares of Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Finally, BTIG Research restated a “buy” rating and issued a $65.00 price objective on shares of Boston Scientific in a research report on Tuesday, June 16th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $79.84.
Get Our Latest Stock Report on BSX
About Boston Scientific (Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Recommended Stories Five stocks we like better than Boston Scientific Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAllspring Global Investments Holdings LLC Has $19.48 Million Stake in Synopsys, Inc. $SNPS
NEXT HEADLINE »Amova Asset Management Americas Inc. Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX
Boston Scientific (BSX - Free Report) closed at $43.19 in the latest trading session, marking a -1.33% move from the prior day. This change lagged the S&P 500's daily gain of 0.89%. At the same time, the Dow added 0.74%, and the tech-heavy Nasdaq gained 1.29%.
Shares of the medical device manufacturer have depreciated by 1.26% over the course of the past month, underperforming the Medical sector's gain of 4.77%, and the S&P 500's loss of 0.63%.
Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on July 29, 2026. The company's earnings per share (EPS) are projected to be $0.83, reflecting a 10.67% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $5.39 billion, reflecting a 6.54% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $3.35 per share and revenue of $21.59 billion, indicating changes of +9.48% and +7.57%, respectively, compared to the previous year.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.15% lower within the past month. Boston Scientific is currently sporting a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Boston Scientific has a Forward P/E ratio of 13.05 right now. This indicates a discount in contrast to its industry's Forward P/E of 19.35.
One should further note that BSX currently holds a PEG ratio of 0.84. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical - Products industry stood at 1.75 at the close of the market yesterday.
The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 167, this industry ranks in the bottom 33% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
BSX faces Q2 results with growth expected in key businesses, but lowered full-year guidance, cost pressures and weak stock performance cloud the outlook.
Allspring Global Investments Holdings LLC reduced its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 49.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 1,093,483 shares of the medical equipment provider’s stock after selling 1,079,916 shares during the period. Allspring Global Investments Holdings LLC owned about 0.07% of Boston Scientific worth $67,796,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after purchasing an additional 1,436,550 shares during the last quarter. State Street Corp lifted its holdings in Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after buying an additional 920,495 shares in the last quarter. Capital World Investors boosted its position in Boston Scientific by 1.9% in the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after buying an additional 502,627 shares during the period. Norges Bank purchased a new stake in Boston Scientific in the 4th quarter valued at about $2,199,395,000. Finally, Morgan Stanley grew its stake in Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after acquiring an additional 2,246,308 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.
Boston Scientific Trading Down 1.5% Shares of NYSE:BSX opened at $43.95 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The stock has a market cap of $65.33 billion, a price-to-earnings ratio of 18.39, a PEG ratio of 0.86 and a beta of 0.58. The business has a 50-day moving average price of $48.18 and a 200-day moving average price of $65.87.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the prior year, the firm earned $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.35 EPS for the current year.
Boston Scientific announced that its board has approved a stock repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
Wall Street Analysts Forecast Growth Several research firms have recently weighed in on BSX. Zacks Research downgraded shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Mizuho dropped their price objective on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research note on Wednesday. Robert W. Baird set a $70.00 price objective on Boston Scientific in a report on Thursday, May 28th. Wolfe Research lowered Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Finally, Bank of America lowered their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a report on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $79.84.
Get Our Latest Stock Report on BSX
Insider Activity In other Boston Scientific news, Director Cheryl Pegus bought 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director David C. Habiger purchased 2,250 shares of the stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. The trade was a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 9,800 shares of company stock valued at $554,012 in the last ninety days. Insiders own 0.34% of the company’s stock.
About Boston Scientific (Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Further Reading Five stocks we like better than Boston Scientific AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident GE Aerospace Faces a Prove-It Moment in Q2 Earnings Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
Boston Scientific (BSX - Free Report) closed at $42.63 in the latest trading session, marking a -4.52% move from the prior day. This change lagged the S&P 500's 0.38% gain on the day. Elsewhere, the Dow saw an upswing of 0.02%, while the tech-heavy Nasdaq appreciated by 0.9%.
Shares of the medical device manufacturer witnessed a loss of 4.51% over the previous month, trailing the performance of the Medical sector with its gain of 4.34%, and the S&P 500's gain of 1.27%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company is scheduled to release its earnings on July 29, 2026. The company's upcoming EPS is projected at $0.83, signifying a 10.67% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $5.39 billion, indicating a 6.54% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $3.36 per share and revenue of $21.61 billion, which would represent changes of +9.8% and +7.65%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Boston Scientific. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.02% lower. At present, Boston Scientific boasts a Zacks Rank of #4 (Sell).
Looking at its valuation, Boston Scientific is holding a Forward P/E ratio of 13.3. This signifies a discount in comparison to the average Forward P/E of 19.3 for its industry.
It is also worth noting that BSX currently has a PEG ratio of 0.85. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.75.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 201, putting it in the bottom 19% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Let's take a look at what these Wall Street heavyweights have to say about Boston Scientific (BSX - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Boston Scientific currently has an average brokerage recommendation (ABR) of 1.48, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 29 brokerage firms. An ABR of 1.48 approximates between Strong Buy and Buy.
Of the 29 recommendations that derive the current ABR, 21 are Strong Buy and four are Buy. Strong Buy and Buy respectively account for 72.4% and 13.8% of all recommendations.
Brokerage Recommendation Trends for BSX
Check price target & stock forecast for Boston Scientific here>>>
The ABR suggests buying Boston Scientific, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABRIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
Is BSX Worth Investing In?In terms of earnings estimate revisions for Boston Scientific, the Zacks Consensus Estimate for the current year has declined 0.2% over the past month to $3.36.
Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Boston Scientific. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, it could be wise to take the Buy-equivalent ABR for Boston Scientific with a grain of salt.
Steve Cohen runs Point72 Asset Management, and investors closely watch his investment decisions through that hedge fund's 13F filings. The most recent 13F highlighted two interesting moves. First, Cohen took profits in artificial intelligence leaders Amazon (AMZN 0.80%) and Nvidia (NVDA +3.74%). Second, he dramatically increased his position in Boston Scientific (BSX 1.08%).
Here's a look at Steve Cohen's stock buying and selling and why you might want to consider making similar investment moves.
Image source: Getty Images.
The AI trade could be changing Since the start of 2026, neither Amazon nor Nvidia have been a particularly strong performer. Amazon and Nvidia were only up around 5% year to date as of this writing, trailing the roughly 10% gain of the S&P 500 index (^GSPC 0.28%). That comes after a multi-year advance for each company.
Over the past decade, Amazon was up over 560% compared to a gain of 260% for the S&P 500 index. Nvidia's stock rose more than 16,000% over the same span. Taking profits from strongly performing stocks is hardly shocking, especially as they start to lag the broader market after a long period of strength.
However, what's notable is that the artificial intelligence trade that helped push these two stocks higher appears to be shifting. The early leaders may be giving way to infrastructure companies, such as hydrogen fuel cell maker Bloom Energy (BE 5.67%), that support the build-out of the AI backbone. Between the fourth quarter of 2025 and the first quarter of 2026, Cohen trimmed his stake in Amazon by 6% and his Nvidia position by a whopping 24%.
NVDA data by YCharts
Cohen is betting on an unloved healthcare giant While Cohen was selling Nvidia and Amazon shares, he was buying Boston Scientific shares. His position in this medical device maker increased by 50% from the start of the year. What's interesting is that the dollar value of the Boston Scientific position barely budged because the stock has been heading sharply lower. It is down over 50% year to date as of this writing. This is a value play, with Cohen likely betting that the company turns its fortunes around over the long term.
Boston Scientific makes medical devices used in cardiac care (66% of revenues) and medical-surgical products (34%). The products it sells are not optional, so demand is steady regardless of economic trends and market cycles. The company has long been a top player in the medical technology space. However, all companies go through good periods and bad ones. Right now, Boston Scientific isn't hitting on all cylinders.
Notably, the company reported a strong first quarter, but provided a particularly weak outlook for the rest of the year. The numbers here speak volumes. In the first quarter of 2026, Boston Scientific posted organic sales growth of 9.4%, but in the second quarter, it projects organic sales growth could slow to as low as 5%. For the full year, the company lowered its adjusted earnings guidance range from $3.43 to $3.49 per share to a range of $3.34 to $3.41.
Today's Change
(
-1.08
%) $
-0.49
Current Price
$
44.81
There's a reason investors are downbeat right now: the new high end of the guidance range is lower than the old low end. But the company has a long history of success, driven by innovation and strong customer relationships. It is one of a small number of medical device makers that have entrenched industry positions. It is highly likely that the company will eventually emerge from its current funk.
Boston Scientific: A deep value opportunity The big story for investors right now, however, is Boston Scientific's valuation. For example, its price-to-sales ratio of 3.2x is far below its five-year average of 6x. And its price-to-earnings ratio of 19x is well below its longer-term average of 64x. To be fair, buying a value-oriented stock like Boston Scientific should be viewed as a long-term investment.
Indeed, you can't turn an over $60 billion market cap healthcare giant around on a dime. But it seems highly likely that this industry-leading medical device maker does, eventually, get back on track. Which is likely what Steve Cohen is betting on, and you might want to, too.
In the latest close session, Boston Scientific (BSX - Free Report) was down 1.2% at $44.60. The stock trailed the S&P 500, which registered a daily gain of 0.72%. On the other hand, the Dow registered a gain of 0.3%, and the technology-centric Nasdaq increased by 1.12%.
The medical device manufacturer's stock has dropped by 7.02% in the past month, falling short of the Medical sector's gain of 12.48% and the S&P 500's loss of 0.9%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company is scheduled to release its earnings on July 29, 2026. The company is forecasted to report an EPS of $0.83, showcasing a 10.67% upward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $5.39 billion, reflecting a 6.54% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.36 per share and a revenue of $21.61 billion, signifying shifts of +9.8% and +7.65%, respectively, from the last year.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.32% lower within the past month. Right now, Boston Scientific possesses a Zacks Rank of #4 (Sell).
In terms of valuation, Boston Scientific is currently trading at a Forward P/E ratio of 13.44. Its industry sports an average Forward P/E of 19.08, so one might conclude that Boston Scientific is trading at a discount comparatively.
We can additionally observe that BSX currently boasts a PEG ratio of 0.86. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry currently had an average PEG ratio of 1.73 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 170, positioning it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
SummaryRelative to its all-time high of $109.50 reached in September 2025, Boston Scientific Corporation's share price has declined by almost 60% to trade at around $45.00 per share.To put my money where my mouth is, I purchased my last shares on June 30th at an average price of $42.83. My overall purchase price now stands at $45.52.As part of its Q1-26 earnings, Boston Scientific announced a significant outlook revision, reducing its organic growth guidance for fiscal 2026 to a range between 6.5% and 8.0%.With a $4.0 billion free cash flow guidance, BSX currently trades at an FCF yield of approximately 6.0%, which is one of the highest in the company's history.Given where the stock is trading, I am encouraged by the $2.0 billion accelerated share repurchase program announced last May. It is quite unusual for Boston Scientific to aggressively repurchase its own shares, as we have to go all the way back to fiscal 2020 to find the last share repurchases. JHVEPhoto/iStock Editorial via Getty Images
From Abbott Laboratories To Boston Scientific After initiating Abbott Laboratories (ABT) with a 'Strong Buy' rating towards the end of April 2026, I now turn my attention to another healthcare giant named Boston Scientific (
3.05K Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of BSX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
In the latest close session, Boston Scientific (BSX - Free Report) was down 1.84% at $42.68. The stock's change was less than the S&P 500's daily gain of 0.79%. Meanwhile, the Dow gained 0.26%, and the Nasdaq, a tech-heavy index, added 1.52%.
The stock of medical device manufacturer has fallen by 9.38% in the past month, lagging the Medical sector's gain of 7.53% and the S&P 500's loss of 1.82%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company is scheduled to release its earnings on July 29, 2026. In that report, analysts expect Boston Scientific to post earnings of $0.83 per share. This would mark year-over-year growth of 10.67%. Meanwhile, the latest consensus estimate predicts the revenue to be $5.39 billion, indicating a 6.54% increase compared to the same quarter of the previous year.
BSX's full-year Zacks Consensus Estimates are calling for earnings of $3.36 per share and revenue of $21.61 billion. These results would represent year-over-year changes of +9.8% and +7.65%, respectively.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.37% fall in the Zacks Consensus EPS estimate. At present, Boston Scientific boasts a Zacks Rank of #4 (Sell).
Looking at its valuation, Boston Scientific is holding a Forward P/E ratio of 12.95. Its industry sports an average Forward P/E of 18.39, so one might conclude that Boston Scientific is trading at a discount comparatively.
We can also see that BSX currently has a PEG ratio of 0.83. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry had an average PEG ratio of 1.65 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 180, positioning it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Boston Scientific has suffered a 50% share price decline amid decelerating growth and competitive threats, but fundamentals-based valuation now appears attractive. Growth in key segments like electrophysiology and Watchman has slowed due to increased competition, reimbursement cuts, and less impressive clinical trial data. Management now guides to sub-10% revenue growth (6.5%-8% for the year), but I still expect 7.5% annualized growth over five years and improving margins.
In the latest close session, Boston Scientific (BSX - Free Report) was down 2.5% at $44.46. The stock trailed the S&P 500, which registered a daily loss of 0.1%. Elsewhere, the Dow gained 0.35%, while the tech-heavy Nasdaq lost 0.43%.
Shares of the medical device manufacturer witnessed a loss of 20.89% over the previous month, trailing the performance of the Medical sector with its gain of 1.97%, and the S&P 500's loss of 1.34%.
Market participants will be closely following the financial results of Boston Scientific in its upcoming release. It is anticipated that the company will report an EPS of $0.83, marking a 10.67% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $5.39 billion, up 6.54% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.36 per share and a revenue of $21.61 billion, signifying shifts of +9.8% and +7.65%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Boston Scientific. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.51% lower. As of now, Boston Scientific holds a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Boston Scientific has a Forward P/E ratio of 13.58 right now. Its industry sports an average Forward P/E of 17.47, so one might conclude that Boston Scientific is trading at a discount comparatively.
Meanwhile, BSX's PEG ratio is currently 0.87. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. BSX's industry had an average PEG ratio of 1.56 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 175, placing it within the bottom 29% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Let's take a look at what these Wall Street heavyweights have to say about Boston Scientific (BSX - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Boston Scientific currently has an average brokerage recommendation (ABR) of 1.52, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 31 brokerage firms. An ABR of 1.52 approximates between Strong Buy and Buy.
Of the 31 recommendations that derive the current ABR, 22 are Strong Buy and four are Buy. Strong Buy and Buy respectively account for 71% and 12.9% of all recommendations.
Brokerage Recommendation Trends for BSX
Check price target & stock forecast for Boston Scientific here>>>
The ABR suggests buying Boston Scientific, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Is BSX Worth Investing In?Looking at the earnings estimate revisions for Boston Scientific, the Zacks Consensus Estimate for the current year has declined 0.5% over the past month to $3.36.
Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Boston Scientific. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, it could be wise to take the Buy-equivalent ABR for Boston Scientific with a grain of salt.
Boston Scientific (BSX - Free Report) closed the most recent trading day at $45.60, moving +2.86% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.44%. Elsewhere, the Dow saw a downswing of 0.09%, while the tech-heavy Nasdaq depreciated by 2.22%.
The stock of medical device manufacturer has fallen by 23.28% in the past month, lagging the Medical sector's gain of 0.57% and the S&P 500's gain of 0.08%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. In that report, analysts expect Boston Scientific to post earnings of $0.83 per share. This would mark year-over-year growth of 10.67%. Simultaneously, our latest consensus estimate expects the revenue to be $5.39 billion, showing a 6.54% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.36 per share and a revenue of $21.61 billion, signifying shifts of +9.8% and +7.65%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.51% downward. Boston Scientific is currently sporting a Zacks Rank of #4 (Sell).
Looking at valuation, Boston Scientific is presently trading at a Forward P/E ratio of 13.2. This valuation marks a discount compared to its industry average Forward P/E of 17.43.
One should further note that BSX currently holds a PEG ratio of 0.85. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. BSX's industry had an average PEG ratio of 1.52 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 167, finds itself in the bottom 32% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Boston Scientific (BSX - Free Report) closed at $44.95 in the latest trading session, marking a -4.2% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 1.22% for the day. On the other hand, the Dow registered a loss of 0.98%, and the technology-centric Nasdaq decreased by 1.35%.
Heading into today, shares of the medical device manufacturer had lost 17.41% over the past month, lagging the Medical sector's gain of 4.11% and the S&P 500's gain of 1.56%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company's upcoming EPS is projected at $0.83, signifying a 10.67% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $5.39 billion, up 6.54% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.36 per share and a revenue of $21.61 billion, signifying shifts of +9.8% and +7.65%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Boston Scientific. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.51% lower. Boston Scientific presently features a Zacks Rank of #4 (Sell).
Looking at valuation, Boston Scientific is presently trading at a Forward P/E ratio of 13.97. This valuation marks a discount compared to its industry average Forward P/E of 17.48.
We can additionally observe that BSX currently boasts a PEG ratio of 0.9. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Products industry had an average PEG ratio of 1.59 as trading concluded yesterday.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 166, which puts it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Boston Scientific (BSX 0.55%) shares have performed poorly in recent months. Year to date, shares in the medtech company have fallen by over 50%.
It's not surprising shares have fallen so far, so fast. Boston Scientific has kept walking back growth expectations all year. However, with the analyst community far more upbeat about it than the market, let's explore this beaten-down healthcare stock's comeback potential.
Image source: Getty Images.
Boston Scientific and its extended slide In February, Boston Scientific's management guided organic sales growth of 10% to 11%. But as 2025 growth was 19.5%, investors reacted poorly to the outlook. Worse yet, management has kept making downward adjustments.
In April, management lowered full-year 2026 organic revenue guidance to between 6.5% and 8%. Then, in late May, management walked things back once again. Citing "the declining usage of Watchman stand-alone procedures," or procedures using Boston Scientific's Watchman heart implant, CEO Michael Mahoney noted that the company will likely report "flat dollar growth from first quarter to second quarter, and likely in the third quarter."
Why the stock's lofty price target may not last Analyst sentiment has shifted bearish, but 27 out of the 31 analysts covering the stock still give it the equivalent of a buy rating. Not only that, the consensus price target of $78 per share represents potential upside of 65%.
While it's plausible that shares could recover on better-than-expected results, even a partial recovery to $78 per share could prove challenging. Boston Scientific currently trades at a forward valuation in the mid-teens, in line with other medical device stocks, such as Abbott Laboratories and Medtronic. A rerating to a premium valuation will likely require a faster-than-expected recovery in growth. Worse yet, depending on Q2 results and guidance, these high price targets could trend lower.
For now, take this wide spread between stock price and price target with a grain of salt.
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and Medtronic. The Motley Fool has a disclosure policy.
It has been about a month since the last earnings report for Boston Scientific (BSX - Free Report) . Shares have lost about 13% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Boston Scientific due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
BSX Q1 Earnings Match, '26 View DownBoston Scientific Corporation (BSX - Free Report) posted first-quarter 2026 adjusted earnings per share (EPS) of 80 cents, up 6.7% from the year-ago figure. The figure matched the Zacks Consensus Estimate.
The quarter’s adjustments included certain amortization expenses, litigation-related net charges and restructuring charges, among others. Reported EPS for the first quarter was 90 cents compared with the year-ago quarter’s 45 cents.
Revenue Details of BSXFirst-quarter revenues totaled $5.20 billion, up 11.6% year over year on a reported basis and up 9.4% on an operational and organic basis. The top line exceeded the Zacks Consensus Estimate by 0.4%.
BSX's Q1 Revenues by RegionsIn the first quarter, revenues rose 10.9% in the United States on a reported basis (same operationally).
Reported revenues increased 10.1% in EMEA, or 1.2% on an operational basis, and 14.7% in Asia Pacific, or 12% operationally.
Reported revenues increased 19% in Latin America and Canada (up 12% operationally).
Breaking Down BSX's Q1 Revenues by SegmentsBoston Scientific recently reorganized its operational structure and aggregated its core businesses into two reportable segments — MedSurg and Cardiovascular. Both these segments generate revenues from the sale of Medical Devices.
MedSurg
MedSurg revenues in the first quarter totaled $1.70 billion, up 7.8% year over year on a reported basis (up 5.7% on an operational and organic basis).
Within this, the Endoscopy unit generated revenues of $736 million, up 6.8% organically and operationally.
Urology revenues amounted to $646 million, reflecting organic and operational growth of 0.5%.
The Neuromodulation business reported $318 million in revenues, reflecting 15.4% year-over-year organic and operational growth.
Cardiovascular
The company generates maximum revenues from this segment. Revenues in the first quarter totaled $3.50 billion, up 13.5% (reportedly) and 11.2% (organically and operationally) year over year.
BSX’s Margin Performance in Q1The gross margin expanded 60 basis points (bps) year over year to 69.4%. There was a 9.4% rise in the cost of products sold (to $1.59 billion) in the reported quarter.
Selling, general and administrative expenses rose 11.5% to $1.78 billion. Research and development expenses rose 16.5% to $516 million. Royalty expenses of $12 million declined 14.3% year over year. Adjusted operating margin expanded 27 bps to 25.1%.
BSX’s Lowered 2026 and Q2 ViewFor 2026, Boston Scientific now anticipates net sales to grow approximately 7-8.5% on a reported basis and 6.5-8% on an organic basis (down from previous growth guidance of 10.5-11.5% on a reported basis and 10-11% on an organic basis). The Zacks Consensus Estimate is currently pegged at $22.27 billion, indicating a 10.9% rise from the 2025 figure.
Full-year adjusted EPS is now expected in the range of $3.34-$3.41 (down from $3.43-$3.49). The Zacks Consensus Estimate is currently pegged at $3.45.
For the second quarter of 2026, revenue growth is projected in the range of approximately 5.5-7.5% on a reported basis (up 5-7% organically). Adjusted earnings are expected to be in the range of 82-84 cents per share.
The Zacks Consensus Estimate for second-quarter earnings and revenues is pegged at 86 cents per share and $5.57 billion, respectively.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review.
VGM ScoresAt this time, Boston Scientific has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a score of C on the value side, putting it in the middle 20% for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Boston Scientific has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
Key Takeaways Boston Scientific's WATCHMAN platform grew 19% in Q1 2026, supporting Structural Heart momentum. BSX's CHAMPION met all endpoints, supporting WATCHMAN safety and efficacy across major markets. Positive trial results may expand BSX's WATCHMAN's addressable market from 5M to 20M patients worldwide. Boston Scientific’s (BSX - Free Report) Structural Heart franchise continues to gain momentum, driven by the robust performance of the WATCHMAN left atrial appendage closure (LAAC) platform. WATCHMAN is the global leader in percutaneous LAAC and serves as a proven non-pharmacologic alternative to oral anticoagulants.
In the first quarter of 2026, WATCHMAN grew 19%, led by the annualization of the initial concomitant adoption tailwind, alongside some softening in standalone WATCHMAN procedures due to hospital capacity constraints, shifting procedure prioritization and evolving reimbursement dynamics.
The company remains focused on clinical expansion. Enrollment in the SIMPLAAFY trial has been completed, with data expected in the second half of 2026. In addition, the CHAMPION trial achieves all primary and secondary endpoints, reinforcing the safety and efficacy of WATCHMAN.
Globally, these results provide strong evidence to support expanding the eligible patient population for WATCHMAN over time across major markets, including the United States, Japan, China and Europe. Positive outcomes expand the addressable market from approximately 5 million to 20 million patients worldwide, supporting WATCHMAN’s long-term growth potential.
Peer UpdateAbbott Laboratories’ (ABT - Free Report) LAAC franchise has been transferred from the Structural Heart division to the Electrophysiology (EP) business, reflecting the increasing convergence of structural and electrophysiology therapies. The EP segment delivered 13% growth, supported by the successful launch of two pulsed field ablation (PFA) catheters during the quarter.
In the United States, the introduction of the Volt PFA catheter drove 14% growth, while the launch of the TactiFlex Duo catheter contributed to mid-teens growth across Europe. In parallel, Abbott continues to advance its next-generation LAAC platform, commonly referred to by investors as the “NextGen 360” device, which is expected to strengthen the company’s position in the expanding stroke prevention market.
Edwards Lifesciences’ (EW - Free Report) Surgical Structural Heart business pioneered the innovative RESILIA tissue, which is backed by more than 40 years of the company’s tissue technology leadership. In first-quarter 2026, the segment grew 6% from the prior-year level, driven by strong global adoption of Edwards’ premium resilient technologies, including INSPIRIS, MITRIS and KONECT.
Edwards has been continuously generating evidence to expand the RESILIA portfolio. Last year, management reported positive one-year results from MOMENTIS, supporting the long-term durability of MITRIS systems for surgical mitral valve replacement. It also unveiled favorable eight-year data showing the strong durability of RESILIA tissue bioprosthetic valves.
BSX Stock Price PerformanceShares of Boston Scientific have lost 44.7% over the past year compared with the industry’s decline of 27.1%. The S&P 500 composite has grown 33% in the same period.
Image Source: Zacks Investment Research
Boston Scientific’s ValuationFrom a valuation standpoint, BSX trades at a forward 12-month price-to-sales ratio (P/S) of 3.83X, above the industry median of 3.01X.
Image Source: Zacks Investment Research
BSX Stock Consensus Estimate TrendThe Zacks Consensus Estimate for BSX’s 2026 earnings has moved south 1.2% over the past 30 days.
Image Source: Zacks Investment Research
BSX stock currently has a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX:BSX OTCQX:BSXGF) today is pleased to announce that each of the six individuals nominated for election as a director of Belo Sun at the Company's Annual and Special Meeting of Shareholders held on May 26, 2026 (the “Meeting”), was elected.
On May 27, 2026, we delve into the DCF analysis for Boston Scientific Corp BSX , a company currently facing significant price performance challenges. Over the past year, BSX has seen a decline of 44.8%, and its year-to-date performance shows a drop of 39.5%. This context is essential as we evaluate its intrinsic value through discounted cash flow models.
DCF Earnings-based intrinsic value: $51.31 vs current price: $57.64 (margin of safety: -12.3%) DCF FCF-based intrinsic value: $68.94 (modestly undervalued with 16.4% margin of safety) GF Score™: 83/100, indicating a high reliability of the DCF inputs What Is BSX Worth? DCF Earnings-Based Model The DCF earnings-based model employs a two-stage approach to estimate the intrinsic value of BSX. In the first stage, we project earnings growth over the next ten years, followed by a terminal phase where growth stabilizes. The assumptions used in this model are critical for accuracy and are summarized in the table below:
Parameter Value Current EPS (TTM, excl. non-recurring) $3.10 10-Year Growth Rate 10.5% 10-Year Treasury Rate 4.47% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% In the growth phase (Years 1-10), we expect the EPS to grow at 10.5% annually, which is then discounted at a rate of 11%. The value derived from this stage is $30.24 per share. In the terminal phase (Years 11-20), we assume a growth rate of 4%, also discounted at 11%, yielding a value of $21.07 per share. The summary of these calculations is as follows:
Stage Description Value Growth Stage (Years 1-10) EPS growing at 10.5%, discounted at 11% $30.24 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $21.07 Intrinsic Value Growth + Terminal $51.31 Comparing the current price of $57.64 with the intrinsic value of $51.31 indicates that BSX is fairly valued, with a margin of safety of -12.3%. It is important to note that GuruFocus utilizes EPS figures excluding non-recurring items, as research indicates a stronger correlation between stock prices and earnings than with free cash flow. For further calculations, you can visit the BSX DCF Calculator.
What Does the Free Cash Flow DCF Say? In addition to the earnings-based DCF model, we also consider the free cash flow (FCF) DCF model, which provides an intrinsic value of $68.94 per share. This figure suggests that BSX is modestly undervalued, with a margin of safety of 16.4%. When comparing the FCF-based intrinsic value with the earnings-based value, we see a divergence in the assessment of BSX's valuation, indicating that while the earnings-based model suggests fair valuation, the FCF model points towards undervaluation.
How Does GF Value™ Compare to the DCF Models? The GF Value™ for BSX stands at $105.01, offering a third perspective on the company's valuation. GF Value™ is GuruFocus' proprietary measure, calculated based on historical trading multiples, past business growth, and future performance estimates. When we analyze the three models—DCF earnings, DCF FCF, and GF Value™—we observe that they present differing views on BSX's valuation, with the DCF earnings model indicating fair value, the FCF model suggesting modest undervaluation, and GF Value™ indicating significant undervaluation. For more details, visit the GF Value™ page.
What Does BSX's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns based on backtested data from 2006 to 2021. Below is a summary of BSX's GF Score™ metrics:
Metric Rating GF Score™ 83/100 Financial Strength 6/10 Profitability 9/10 Growth 10/10 Valuation 4/10 Momentum 2/10 With a predictability rank of 1 out of 5 stars, it is important to note that higher predictability ratings generally lead to more reliable DCF estimates for stocks. For more information, visit the BSX stock page.
Key Assumptions and Limitations It is crucial to recognize that DCF models are highly sensitive to the assumptions made regarding growth rates and discount rates. Stocks with low predictability ratings, such as BSX, tend to produce less reliable DCF estimates. The terminal growth rate of 4% is a simplifying assumption that may not accurately reflect future market conditions.
What This Means for Investors In synthesizing the insights from the three valuation models—DCF earnings, DCF FCF, and GF Value™—we find that BSX presents a mixed picture. The earnings-based model suggests fair valuation, while the FCF model indicates modest undervaluation, and the GF Value™ suggests a more significant undervaluation. Overall, this leads to a conclusion that BSX is fairly valued based on earnings but may be seen as undervalued from a cash flow perspective.
For the full DCF analysis, visit the BSX DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.
Frequently Asked Questions What is BSX's intrinsic value based on DCF?
[Answer: earnings-based $51.32, FCF-based $68.94]
Is BSX overvalued or undervalued?
[Answer using DCF + GF Value™ consensus]
How reliable is the DCF model for BSX?
[Answer using predictability rank 1/5]
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
It's commonplace for companies in the healthcare space to buy their way into new markets and product categories. Boston Scientific (BSX 0.32%), a top healthcare stock and medical device company, recently announced it was investing $1.5 billion in MiRus LLC for an approximate 34% stake in the business.
The investment gives Boston Scientific a foothold in the transcatheter aortic valve replacement (TAVR) market, which Grand View Research estimates could grow from $4.5 billion in 2024 to $12.2 billion by 2033. The announcement happened a week ago, and thus far, Wall Street isn't showing any loss of love for the stock. Of 36 analysts polled by CNN Business, 92% have rated Boston Scientific a buy.
Here's more about Boston Scientific's investment, and what it could mean for investors.
Image source: Getty Images.
The fine print reveals that an even bigger transaction could be lurking Transcatheter aortic valve replacement is a treatment for aortic valves in the human heart that are too narrow to open properly. MiRus is developing the proprietary Siegel TAVR system; it's the first nickel-free, balloon-expandable TAVR valve intended to restore function and normal blood flow to severely narrowed aortic valves.
Boston Scientific will immediately own about a third of the company with this initial investment, but the deal also lays the groundwork for a potential 100% acquisition. If the MiRus TAVR system meets the appropriate milestones, Boston Scientific has the option to pay up to an additional $3 billion to acquire it.
It's a clever deal because it paves the way for the acquisition without risking the full amount should the system ultimately fail. The only real downside is that it won't contribute anything to Boston Scientific's earnings in 2026, so there's no immediate return on that capital.
Today's Change
(
-0.32
%) $
-0.15
Current Price
$
47.02
Wall Street could be following the insiders Sure, 92% of analysts on CNN Business rate Boston Scientific as a buy, but that alone shouldn't be a reason for an individual investor to buy a stock. It does help the case when insiders, key employees at the company, begin scooping up shares. Regulatory filings on May 21 revealed that three directors at the company recently purchased shares worth a total of over half a million dollars.
Additionally, Boston Scientific recently announced a $2 billion accelerated buyback program, in which it purchases its own shares on the open market ahead of its previously announced schedule. It's a pretty loud signal that management views the stock's valuation favorably.
Wall Street analysts estimate that Boston Scientific will grow earnings by over 16% annually over the next three to five years. The stock is currently a bargain, trading at just 17 times 2026 earnings estimates, assuming earnings grow at or near that pace.
Boston Scientific had already laid the groundwork for growth and was a compelling buy last week. Now, the future could be even brighter, with a groundbreaking new product potentially opening a massive new market for the company.
Boston Scientific (BSX 0.32%), a medical device maker for interventional specialties, closed Wednesday at $50.42, down 12.53%. The stock dropped after management reiterated soft full-year organic growth guidance and flagged softer demand in key WATCHMAN and urology franchises. Trading volume reached 49.5 million shares, about 191% above its three-month average of 17 million shares. Boston Scientific IPO'd in 1992 and has grown 1,078% since going public.
How the markets moved todayS&P 500 inched up 0.03% to 7,521, while the Nasdaq Composite added 0.07% to finish at 26,675. Within medical devices, industry peers Abbott Laboratories closed at $85.68 (-1.14%) and Stryker ended at $305.99 (-2.24%), reflecting broader pressure across sector rivals.
What this means for investorsInvestors were hoping for a positive update from Boston Scientific at the Bernstein Annual Strategic Decisions Conference today, but management merely reiterated its previous guidance for the year. The company projects that organic sales will rise between 5.5% to 7% in 2026 and by 6% to 8% in Q2. However, due to expectations for its key WATCHMAN device to deliver flat sequential sales growth in Q2 and Q3, analysts believe the lower end of this guidance may be more realistic.
While the WATCHMAN device was supposed to be a core growth driver for the company, it remains the market share leader in its niche despite its growth slowdown. Trading at 15 times forward earnings after its stock has been halved, BSX stock and its broad portfolio of medical devices aren’t outrageously valued.
Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.
Butterfield Announces Agreement to Acquire Control of CIBC Caribbean in $1.8 Billion Transaction The Bank of N.T. Butterfield & Son Limited (“Butterfield”) (NYSE: NTB | BSX: NTB.BH) has entered into a definitive agreement to acquire CIBC’s 91.7% interest in CIBC Caribbean Bank Limited (“CIBC Caribbean”), a relationship bank with a longstanding history serving communities across the Caribbean, to create a leading banking and wealth management platform in international financial centers and attractive Caribbean markets, with approximately $29 billion in assets. The transaction brings together two complementary banks with deep roots and established relationships across their combined footprint with heightened capacity, greater diversification and scalable growth to drive long-term value for all stakeholders.
Butterfield and CIBC Caribbean’s expanded capabilities and scale are expected to provide enhanced corporate, personal and wealth management services across their combined client bases. Clients can expect greater ability to process cross-border payments, increased consumer and merchant banking capabilities, and continued investments in technology and digital banking infrastructure. Butterfield will maintain both organizations’ operational footprints, including CIBC Caribbean’s regional headquarters in Barbados, ensuring continuity for customers and employees. Butterfield is also committed to its and CIBC Caribbean’s philanthropic, financial education, and sustainability initiatives in each of their geographies, which will continue to provide outsized, tangible and mutually beneficial financial impacts for the combined company and its communities.
Michael Collins, Butterfield’s Chairman and Chief Executive Officer, said: “Since Butterfield’s 2016 listing on the NYSE, we have successfully grown and enhanced profitability through bank and trust acquisitions. This deal combines two storied and complementary banks, with significant local scale advantages and time-honored customer relationships in their respective core jurisdictions. The transaction will offer both scale and diversification to the benefit of all stakeholders, positioning Butterfield as a leading independent bank and wealth manager operating across international financial centers and attractive Caribbean markets. I look forward to welcoming our talented new colleagues and valued clients.”
Mark St. Hill, Chief Executive Officer of CIBC Caribbean, added:“For our clients, employees and communities, this combination brings together two organizations with shared values and a common focus on relationship banking, innovating and community impact. We look forward to building on our legacy as the region’s champion in financial services.”
Harry Culham, President and CEO, CIBC, commented:"The entire CIBC Caribbean team led by Mark St. Hill has built a strong, client-focused bank across the region, and we look forward to realizing the strategic benefits of this transaction to deliver more for all stakeholders.”
Transaction Details
The total consideration to be paid for CIBC Caribbean will be comprised of $1,091 million in cash and $703 million in Butterfield shares valued by reference to Butterfield’s 10-day NYSE VWAP of $55.66 as of May 27, 2026, for an aggregate purchase price of $1,794 million, or $1.14 per CIBC Caribbean share.
Under the terms of the agreement, which have been unanimously approved by the Board of Directors of Butterfield, Butterfield will acquire CIBC Investments (Cayman) Limited, the holding company for CIBC’s 91.7% interest in CIBC Caribbean. Butterfield will subsequently commence a mandatory take-over bid for the remaining 8.3% of total outstanding shares of CIBC Caribbean held by minority shareholders, with the objective of acquiring full ownership of CIBC Caribbean, subject to applicable law and regulatory requirements.
CIBC Caribbean’s minority shareholders will be offered equivalent economic terms as CIBC, and will also have the option to elect to receive up to 100% of their consideration in Butterfield shares, providing them with the opportunity to maintain the entirety of their investment in the combined organization, should they choose to do so. Houlihan Lokey, acting as financial advisor to the Special Committee of CIBC Caribbean’s Board of Directors, has provided an opinion to the Special Committee with respect to the fairness from a financial point of view of the consideration to be offered to CIBC Caribbean’s minority shareholders in the mandatory take-over bid. Assuming minority shareholders elect the same mix of cash and shares as CIBC, following completion of the take-over bid they would collectively own approximately 2% of Butterfield.
In connection with the transaction, Butterfield has obtained commitments for $700 million of Tier 2 capital-qualifying subordinated debt financing expected to be raised prior to closing. Following completion of the transaction, the combined company is expected to maintain capital levels significantly above applicable regulatory thresholds on a consolidated basis, with a pro forma Common Equity Tier 1 (CET1) ratio above 12%, and total capital above 19% at closing.
The transaction is expected to close in the first half of 2027, subject to receipt of Butterfield shareholder and regulatory approvals and the satisfaction of customary closing conditions. Following the transaction, Butterfield’s ordinary shares will continue to be listed on the New York Stock Exchange (NYSE) and the Bermuda Stock Exchange (BSX), and Butterfield intends to undertake additional secondary share listings on the Barbados Stock Exchange (BSE), the Bahamas International Securities Exchange (BISX), and the Trinidad & Tobago Stock Exchange (TTSE), subject to local listing and regulatory requirements.
Following completion of the transaction, CIBC will own an approximately 22% stake in the combined entity. Under the terms of Butterfield and CIBC’s shareholder agreement, CIBC will then initially have the right to appoint two directors to Butterfield’s Board. The shareholder agreement will also provide for certain lockup restrictions with respect to CIBC’s stake in Butterfield, and include customary standstill obligations and registration rights.
The Bermuda Monetary Authority (BMA) will continue to serve as the consolidated regulatory supervisor of Butterfield across all of its locations. Butterfield will also collaborate with all relevant jurisdictional authorities to ensure continuity, market confidence, and access to high-quality financial services within each jurisdiction.
Financial Highlights
Total purchase price of $1,794 million, or $1.14 per CIBC Caribbean share, representing 106% of CIBC Caribbean’s tangible book value as of January 31, 2026 Consideration is 61% cash ($1,091 million) and 39% ($703 million) Butterfield shares Consideration per CIBC Caribbean share of $0.6918 in cash and 0.008008 in Butterfield shares based on the 10-day NYSE VWAP of $55.66 as of May 27, 2026 Butterfield has obtained commitments for $700 million of Tier 2 capital-qualifying subordinated debt financing Pro forma Common Equity Tier 1 (CET1) ratio above 12%, and total capital above 19% at closing 12% expected accretion to GAAP EPS in year 1 with fully phased-in synergies, excluding integration costs 15% expected accretion to cash EPS in year 1 with fully phased-in synergies, excluding integration costs, rate marks and transaction-related amortization 10% expected accretion to Butterfield’s tangible book value per share Internal rate of return of 20%+ Pre-tax cost savings expected to reach an annual run rate of approximately $49 million once fully phased in by 2030 Advisors
Barclays is serving as lead financial advisor to Butterfield, and Sullivan & Cromwell, Carey Olsen and Lex Caribbean are serving as legal advisors. BofA Securities is serving as financial advisor to Butterfield’s Board of Directors.
H/Advisors is serving as communications advisor to Butterfield.
Wachtell, Lipton, Rosen & Katz, Torys LLP and Chancery Chambers are serving as legal advisors to CIBC.
CIBC Capital Markets is serving as financial advisor to CIBC Caribbean, and Mayer Brown LLP is serving as legal advisor. Houlihan Lokey is serving as financial advisor to the Special Committee of CIBC Caribbean’s Board of Directors.
Finer Points Consultants is serving as communications advisor to CIBC Caribbean.
Investor Call
Butterfield will host a conference call for investors and analysts on Thursday, May 28, 2026 at 8:15 a.m. Eastern Time to discuss the transaction.
Dial-in information: +1 (844) 855 9501 (toll-free US) or +1 (412) 858 4603 (international)
Conference ID: Butterfield Group
Live audio webcast: A live audio webcast of the call can be accessed via Butterfield’s investor relations page on Butterfield’s website at https://www.butterfieldgroup.com/investor-relations/events-presentations
Replay: An audio replay of the call will be available at https://www.butterfieldgroup.com/investor-relations/events-presentations
Website
You can also learn more about today’s announcement at https://www.butterfieldgroup.com/future
Forward-Looking Statements
Certain of the statements made in this press release are forward-looking statements within the meaning of, and subject to the protections of, Section 27A of the Securities Act, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts and include statements with respect to, among other things, our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, including, without limitation, statements regarding the proposed acquisition of CIBC Caribbean by Butterfield; the expected timing, structure, terms and completion of the proposed transaction; the expected form and mix of consideration, including the issuance of Butterfield ordinary shares; any acquisition of shares from minority shareholders of CIBC Caribbean or related compulsory acquisition, squeeze-out or similar process; the expected ownership, governance, management, capital, regulatory and operating profile of Butterfield following the proposed transaction; the expected financing of the proposed transaction, including the amount, terms and timing of the proposed subordinated debt financing; and the anticipated benefits of the proposed transaction, including expected scale, diversification, cost savings, synergies, earnings accretion, tangible book value per share accretion, capital generation, regulatory capital ratios, risk-weighted assets, liquidity, deposit mix, market position and other financial and operating impacts.
Forward-looking statements involve known and unknown risks, uncertainties and other factors, many of which are beyond Butterfield’s control, which may cause the actual results, performance, capital, ownership, financial condition or achievements of Butterfield to be materially different from future results, performance, capital, ownership, financial condition or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Butterfield’s ability to successfully complete the proposed acquisition of CIBC Caribbean on the anticipated terms or timeline or at all; Butterfield’s ability to realize the anticipated benefits of the proposed transaction in the expected timeframes or at all, including cost savings, synergies, capital and balance sheet optimization initiatives, earnings accretion, and tangible book value per share accretion; Butterfield’s ability to successfully integrate CIBC Caribbean’s businesses, operations, systems, controls, compliance programs, risk management framework, personnel and culture into those of Butterfield; the risk that such integration may be more difficult, time-consuming or costly than expected; the failure of any of the conditions to the proposed transaction to be satisfied or waived; the failure to obtain required shareholder, regulatory, governmental, securities exchange, exchange-control or other approvals, or delays in obtaining such approvals; the risk that such approvals may result in the imposition of conditions, restrictions or requirements that could adversely affect Butterfield, CIBC Caribbean or the expected benefits of the proposed transaction potentially materially or that any proposed conditions, restrictions or requirements or other actions of regulatory or governmental bodies or securities exchanges could delay or prevent the closing of the proposed transactions; the risk that any minority shareholder offer, compulsory acquisition, squeeze-out or similar process is delayed, not completed or completed on different terms than expected; revenues following the proposed transaction being lower than expected; operating costs, customer loss and business disruption, including difficulties in maintaining relationships with employees, customers, clients, depositors, vendors, suppliers, regulators and other business partners, being greater than expected; risks associated with the disruption of management’s attention from Butterfield’s ongoing business operations due to the proposed transaction; reputational risks and potential adverse reactions to the announcement, pendency or completion of the proposed transaction; the outcome of any legal, regulatory or shareholder proceedings, inquiries or investigations that may be instituted or arise in connection with the proposed transaction; the possibility that the proposed transaction may be more expensive to complete than anticipated, including as a result of unexpected transaction, integration, restructuring, financing, litigation, regulatory, tax, accounting or other costs; dilution caused by the issuance of additional Butterfield ordinary shares in connection with the proposed transaction; changes in Butterfield’s share price, interest rates, foreign exchange rates, capital markets or other market conditions that may affect the transaction financing or expected financial impacts of the proposed transaction; the risk that any subordinated debt or other transaction financing is not obtained on the expected terms, timing or at all; and the risk that assumptions underlying pro forma financial information, purchase accounting, credit marks, fair value marks, integration costs, cost savings, synergies, capital ratios, earnings accretion, tangible book value per share accretion, return metrics and other financial impacts prove to be inaccurate.
Other factors that may impact Butterfield’s future results, performance, financial condition or achievements include worldwide and regional economic conditions, including economic growth and general business conditions in Bermuda, the Cayman Islands, Barbados, The Bahamas, Turks and Caicos, Trinidad and Tobago, the broader Atlantic, Caribbean and other markets in which Butterfield or CIBC Caribbean operates; fluctuations in interest rates, inflation, monetary policy, foreign exchange rates, capital markets, tourism, real estate markets and sovereign credit ratings, including a decline in Bermuda’s sovereign credit rating; any sudden liquidity crisis; changes in customer behavior, including customer borrowing, repayment, investment and deposit practices; unfavorable developments concerning asset quality, credit quality, loan losses, non-performing loans, collateral values, loan concentrations, sovereign exposures, residential mortgage risk weighting, reserves, funding costs, liquidity and deposit flows; competitive product and pricing pressures; security risks, including cybersecurity, data privacy, fraud, financial crime, anti-money laundering and sanctions risks; the impact, extent and timing of technological changes, systems conversions and operational resilience initiatives; risks relating to the success of Butterfield’s updated systems and platforms; capital management activities; changes in laws, regulations, accounting standards, tax laws, regulatory capital or liquidity requirements and supervisory expectations; potential impacts of climate change, hurricanes and other natural disasters; compliance with regulatory requirements; and other factors.
Forward-looking statements can be identified by words such as "anticipate," "assume," "believe," "estimate," "expect," "indicate," "intend," "may," "plan," "point to," "predict," "project," "seek," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions, although not all forward-looking statements contain these identifying words. All statements other than statements of historical fact are statements that could be forward-looking statements.
All forward-looking statements in this disclosure are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our SEC reports and filings, including under the caption "Risk Factors" in our most recent Annual Report on Form 20-F and in any subsequent reports furnished or filed with the Securities and Exchange Commission ("SEC"). Such reports are available upon request from Butterfield, or from the SEC including through the SEC’s website at https://www.sec.gov. Any forward-looking statements made by Butterfield are current views as at the date they are made. Except as otherwise required by law, Butterfield assumes no obligation and does not undertake to review, update, revise or correct any of the forward-looking statements included in this disclosure, whether as a result of new information, future events or other developments. You are cautioned not to place undue reliance on the forward-looking statements made by Butterfield in this disclosure. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, and should only be viewed as historical data.
About Butterfield:
Butterfield is a full-service bank and wealth manager headquartered in Hamilton, Bermuda, providing services to clients from Bermuda, the Cayman Islands, Guernsey and Jersey, where our principal banking operations are located, and The Bahamas, Switzerland, Singapore and the United Kingdom, where we offer specialized financial services. Banking services comprise deposit, cash management and lending solutions for individual, business and institutional clients. Wealth management services are composed of trust, private banking, asset management and custody. In Bermuda, the Cayman Islands and Guernsey, we offer both banking and wealth management. In The Bahamas, Singapore and Switzerland, we offer select wealth management services. In the UK, we offer residential property lending. In Jersey, we offer select banking and wealth management services. Butterfield is publicly traded on the New York Stock Exchange (symbol: NTB) and the Bermuda Stock Exchange (symbol: NTB.BH). Further details on the Butterfield Group can be obtained from our website at: www.butterfieldgroup.com.
About CIBC Caribbean:
CIBC Caribbean is a relationship bank offering a full range of market leading financial services through our Corporate Banking, Personal and Business Banking and Private Wealth segments. CIBC Caribbean is located in ten (10) countries around the Caribbean, providing banking services through approximately 2,700 employees in 41 branches and offices. CIBC Caribbean also has a representative office in Hong Kong that provides business development and relationship management for its fund administration business.
About CIBC:
CIBC is a leading North American financial institution with 15 million personal banking, business, public sector and institutional clients. Across Personal and Business Banking, Commercial Banking and Wealth Management, and Capital Markets, CIBC offers a full range of advice, solutions and services through its leading digital banking network, and locations across Canada, in the United States and around the world.
BF-All
View source version on businesswire.com: https://www.businesswire.com/news/home/20260528619464/en/
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Considering buying BSX stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Boston Scientific (BSX - Free Report) ended the recent trading session at $49.11, demonstrating a -2.68% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.58%. Meanwhile, the Dow gained 0.05%, and the Nasdaq, a tech-heavy index, added 0.91%.
The medical device manufacturer's stock has dropped by 11.71% in the past month, falling short of the Medical sector's gain of 2.82% and the S&P 500's gain of 4.96%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. On that day, Boston Scientific is projected to report earnings of $0.84 per share, which would represent year-over-year growth of 12%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.41 billion, up 6.82% from the year-ago period.
BSX's full-year Zacks Consensus Estimates are calling for earnings of $3.37 per share and revenue of $21.67 billion. These results would represent year-over-year changes of +10.13% and +7.95%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.09% decrease. At present, Boston Scientific boasts a Zacks Rank of #4 (Sell).
In terms of valuation, Boston Scientific is presently being traded at a Forward P/E ratio of 14.96. This valuation marks a discount compared to its industry average Forward P/E of 18.52.
We can also see that BSX currently has a PEG ratio of 0.93. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 1.52.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Boston Scientific (BSX 0.32%) stock was tumbling notably this week. Management admitted weakness in one of the medical device maker's product lines. This, combined with several bearish analyst adjustments, was pushing the shares down by 15% week to date as of early Friday morning, according to data compiled by S&P Global Market Intelligence.
A disheartening forecast On Wednesday, at this year's Bernstein's Annual Strategic Decisions Conference, Boston Scientific CEO Mike Mahoney said sales of its Watchman line of heart implants might be stagnating.
He added that revenue from these formerly thriving products is likely to be flat sequentially in both the current second quarter and the following frame. The CEO attributed this to a shift toward concomitant rather than stand-alone procedures.
Image source: Getty Images.
Zooming out, Mahoney and his team maintained their guidance for the entirety of Boston Scientific's 2026, with organic revenue growth of 6.5% to 8%.
Following this, several analysts tracking Boston Scientific stock published updates on their takes, which trended bearish. One, Lawrence Biegelsen of big bank Wells Fargo, went as far as to downgrade his recommendation on the stock to equal weight (i.e., hold) from overweight (buy). He also reduced his price target to $55 per share from the previous $75.
According to reports, Biegelsen expressed concern about the new Watchman forecast and pointed out that medications currently under development by top pharmaceutical companies could increase competitive pressure. He also cited weakness in other product categories, such as urology.
Today's Change
(
-0.32
%) $
-0.15
Current Price
$
47.02
Better days ahead? Boston Scientific has been an outperformer in years past, and, to a degree, it's been a victim of its own success lately. Not long ago, fourth-quarter and full-year 2025 results disappointed Mr. Market, in part because the company provided relatively tepid guidance.
Yet it's still a powerhouse in the medical device field, which is sure to grow as the population ages. Boston Scientific has numerous product lines beyond Watchman that could grow encouragingly, so I'd view this week's slump as an opportunity to get a fine stock in a vibrant industry at a discount.
Wells Fargo is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Key Takeaways Boston Scientific posted 11.6% sales growth, led by WATCHMAN and FARAPULSE demand. Abbott completed the Exact Sciences acquisition, expanding its cancer diagnostics business. BSX carries a higher analyst upside target, while ABT trades at a lower forward P/S multiple. In the past year, shares of Boston Scientific (BSX - Free Report) and Abbott Laboratories (ABT - Free Report) have lost 53% and 35%, respectively, significantly underperforming the S&P 500’s 31.4% gain. U.S. medical stocks are facing pressure in 2026 due to restrictive regulatory changes, lower-than-expected government reimbursement rates and evolving healthcare policies.
Despite these hurdles, both Boston Scientific and Medtronic delivered robust first-quarter 2026 financial results. It is time for investors to assess whether this momentum can extend through 2026. Let’s find out.
Image Source: Zacks Investment Research
The Case for BSXBoston Scientific reported strong sales growth of 11.6% on a reported basis, exceeding the company’s guidance of 10.5% to 12.0%. Across its key business segments, MedSurg delivered net sales growth of 7.8%, while Cardiovascular grew 13.5%. The company continued to see strong demand for its WATCHMAN left atrial appendage closure (LAAC) platform and FARAPULSE pulsed field ablation (PFA) platform, which remained key growth drivers during the quarter.
During the quarter, Boston Scientific dealt with multiple operational challenges that led management to reduce full-year guidance. In the WATCHMAN franchise, stand-alone procedure volumes weakened amid hospital capacity limitations, reimbursement changes, workflow disruptions and an increasing shift toward concomitant procedures. The company’s EP segment also experienced heightened competitive intensity, contributing to larger-than-anticipated market-share losses, especially in the U.S. market.
Within Urology, the stone business was affected by China’s volume-based procurement (VBP) program and product gaps in the core portfolio. The company also highlighted supply-chain disruptions in Endoscopy, inventory charges related to the discontinuation of the POLARx cryoablation system and discontinuation of the ACURATE platform, which mainly affected the EMEA region.
Boston Scientific also noted the impact of the Middle East conflict on its Cardiac Rhythm Management business. Overall, management acknowledged that 2026 has become a more challenging year than initially anticipated due to these operational, competitive, and macroeconomic pressures.
The Case for ABTAbbott reported first-quarter sales growth of 7.8% on a reported basis. The quarter also marked a significant strategic milestone with its acquisition of Exact Sciences. The deal adds a high-growth business to Abbott’s portfolio, strengthening its leadership position in Diagnostics while expanding its presence in the rapidly growing cancer-diagnostics market.
Abbott also advanced several initiatives within its Medical Devices pipeline during the quarter. The company received earlier-than-expected regulatory approval and launched two new PFA catheters. It completed patient enrollment for its Catalyst left atrial appendage device trial and began development activities for an implantable extravascular ICD product.
Pressure persisted within Abbott’s Core Laboratory Diagnostics business because of China’s volume-based procurement (VBP) program and ongoing COVID-related disruptions. Although the Chinese market has started to stabilize, pricing compression and volume pressure linked to VBP continue to weigh on the business.
Abbott implemented strategic pricing actions in late 2025 to improve competitiveness and support volume recovery within the Nutrition business. Per the latest update, the business is still in an early recovery phase and requires further execution and new product launches to return to stronger growth. Within the Diabetes Care segment, continuous glucose monitoring (CGM) growth was affected by delays in the renewal process for an international tender, as well as challenging year-over-year comparisons tied to inventory restocking activity in the prior-year period.
Abbott identified macroeconomic and geopolitical uncertainty as ongoing risk factors. The company is monitoring potential impacts from the Middle East conflict, including pressure on freight availability, shipping logistics, oil and resin costs, and broader supply-chain disruptions. Although the direct financial impact remained limited during the first quarter, Abbott noted operational challenges related to ensuring timely product deliveries into affected regions.
Valuation: BSX vs. ABTBoston Scientific currently trades at a forward, one-year, price-to-sales (P/S) of 3.25X, lower than its median. Abbott’s 2.87X P/S also sits below its median. Abbott trades cheaper than Boston Scientific.
Image Source: Zacks Investment Research
Short Term Price Target Favors BSX Over ABTBSX: Based on short-term price targets offered by 28 analysts, the average price target of $84.25 represents an increase of 66.96% from the last closing price.
Image Source: Zacks Investment Research
ABT: Based on short-term price targets offered by 24 analysts, the average price target of $ 119.00 represents an increase of 38.89% from the last closing price.
Image Source: Zacks Investment Research
End NoteBoston Scientific delivered strong quarterly growth, supported by robust demand for its WATCHMAN and FARAPULSE platforms. However, the company faced several headwinds during the quarter, prompting management to lower its full-year outlook.
Abbott also reported solid first-quarter growth, driven by the acquisition of Exact Sciences and continued progress across its Medical Devices pipeline. Despite these positives, the company continued to face pressure from ongoing macroeconomic and geopolitical uncertainties, including supply-chain and logistics risks linked to the Middle East conflict.
Both BSX and ABT currently carry a Zacks Rank #4 (Sell), suggesting that existing shareholders may want to consider reducing or exiting their positions. However, based on valuation and one-year stock-price performance, ABT appears better positioned than BSX at current levels.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTC: BSXGF) (the “Company” or “Belo Sun”) provides the following updates regarding a recent petition filed by the Brazilian Federal Prosecution Service (“MPF”) in civil public action No. 1002764-28.2025.4.01.3903 before the Federal Court of Altamira, Pará, Brazil.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Boston Scientific (BSX - Free Report) .
Boston Scientific currently has an average brokerage recommendation (ABR) of 1.45, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 31 brokerage firms. An ABR of 1.45 approximates between Strong Buy and Buy.
Of the 31 recommendations that derive the current ABR, 22 are Strong Buy and four are Buy. Strong Buy and Buy respectively account for 71% and 12.9% of all recommendations.
Brokerage Recommendation Trends for BSX
Check price target & stock forecast for Boston Scientific here>>>
The ABR suggests buying Boston Scientific, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Should You Invest in BSX?In terms of earnings estimate revisions for Boston Scientific, the Zacks Consensus Estimate for the current year has declined 0.2% over the past month to $3.37.
Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Boston Scientific. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, it could be wise to take the Buy-equivalent ABR for Boston Scientific with a grain of salt.
Boston Scientific (BSX - Free Report) ended the recent trading session at $48.85, demonstrating a +2.43% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.41%. Meanwhile, the Dow gained 1.73%, and the Nasdaq, a tech-heavy index, lost 0.09%.
Prior to today's trading, shares of the medical device manufacturer had lost 14.84% lagged the Medical sector's gain of 0.14% and the S&P 500's gain of 4.59%.
Investors will be eagerly watching for the performance of Boston Scientific in its upcoming earnings disclosure. The company is expected to report EPS of $0.83, up 10.67% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.4 billion, up 6.63% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $3.37 per share and revenue of $21.64 billion, which would represent changes of +10.13% and +7.81%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Boston Scientific. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.22% lower within the past month. Boston Scientific presently features a Zacks Rank of #4 (Sell).
Digging into valuation, Boston Scientific currently has a Forward P/E ratio of 14.16. For comparison, its industry has an average Forward P/E of 16.76, which means Boston Scientific is trading at a discount to the group.
We can also see that BSX currently has a PEG ratio of 0.89. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.45.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 160, finds itself in the bottom 35% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
June 08, 2026 07:00 ET | Source: Belo Sun Mining Corp.
TORONTO, June 08, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTCQX: BSXGF) (the “Company” or “Belo Sun”) today announced a change to its in-country executive leadership team as the Volta Grande Gold Project advances toward its next phase of development.
The Company announced that Adriano Espeschit will no longer serve as President, Brazil. Clovis Torres, the Company's Chief Executive Officer, will assume the role of interim President of Brazilian operations effective immediately while the Company conducts a search for a permanent appointment to lead the project through the construction phase.
The Board is confident this transition will ensure continuity of the Company's operations in Brazil and the continued advancement of the Volta Grande Gold Project while the Company looks to strengthen its in-country management team to prepare for the next phase of development as the Project advances toward construction.
About the Company
Belo Sun is a Canadian-based mining company with a portfolio of gold-focused properties in Brazil. The Company is currently focused on the development of the Volta Grande Gold Project. Belo Sun trades on the Toronto Stock Exchange under the symbol “BSX” and on the OTCQX under the symbol “BSXGF”. For more information, please visit www.belosun.com or contact Investor Relations at [email protected] or 1-888-516-4171.
Caution regarding forward-looking information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding the planned leadership transition and the appointment of an interim President of Brazilian operations, the Company’s intention to strengthen its in-country management team, the search for a permanent appointment to lead the Project through the construction phase, and the continued advancement of the Volta Grande Gold Project. Forward-looking information is based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. These factors include, without limitation, changes in the regulatory environment, risks related to the ability of the Company to attract and retain qualified personnel, the ability of the Company to advance the Volta Grande Gold Project to the construction phase, and other risks described in the Company’s filings with Canadian securities regulatory authorities, including the Company’s most recent Annual Information Form. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Disclaimer: All research, figures, and interpretation are provided on a best-effort basis only and may be subject to error. Any view, opinion, or analysis does not constitute as investment or trading advice; please do your own due diligence.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
